Abstract: The present invention provides pharmaceutical compositions comprising an iodine-containing compound and a steroid, useful for treating a clinical symptom in a patient's airway (e.g., nose, lung, and sinus), as well as methods for using the same.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; psoriasis; ocular discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms) in post-menopausal women; post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

Abstract: The present invention provides aqueous in-situ gel ophthalmic formulations, each including water, difluprednate and a biocompatible polysaccharide, wherein a gel is formed in situ at physiological temperature with instant viscosity increase upon instillation of the formulation into an eye. In the formulations, nanocarriers may be formed by a surfactant or solubilizer contained in the formulation, with or encapsulating difluprednate, and the nanocarriers have an average particle size of 10 to 500 nm or 10 to 150 nm or 10- to 50 nm.

Abstract: The present invention provides aqueous formulations containing povidone iodine to be topically applied into a body cavity such as nose of a subject. The formulations of this invention are useful for treating a disease or symptom related to or caused by infection of COVID-19 virus or influenza virus H1N1.

Abstract: The present invention provides aqueous formulations containing an anti-infection agent, a biocompatible polysaccharide, an osmotic pressure regulator, a pH regulator, and water, wherein a gel containing the therapeutic agent is formed in situ upon instillation of the formulations onto the skin and a body cavity of a subject. The formulations of this invention are useful for treating infectious diseases of skin or a body cavity (e.g., eye, nose, or vagina) of a subject.

Abstract: The present invention provides pharmaceutical compositions comprising an antiseptic and a steroid, useful for treating a clinical symptom in a patient's airway (e.g., nose, lung, and sinus), wherein a gel containing the antiseptic is formed in situ upon instillation of the compositions onto a body cavity of a subject, as well as methods for using the same.

Abstract: The present invention provides thin-film forming compositions comprising an antiseptic (e.g., povidone iodine, chlorhexidine, or octenidine), a non-aqueous solvent, and a film-forming material dissolved in the non-aqueous solvent, wherein the composition yields a continuous and flexible protective film upon substantial removal of the solvent. The compositions are useful for the treatment and prevention of infections in wounds, ulcers (e.g., decubitus ulcers and stasis ulcers), cuts, or burns, or against infections from bacterial, mycobacterial, viral, fungal, or amoeba causes, as well as for prevention of such infections in appropriate clinical settings (e.g., as liquid bandages or dressings). Additionally, the compositions of this invention are also useful for the treatment of infections and as a disinfectant skin preparation for pre- and/or post-surgical operations.

Abstract: The present invention provides a pharmaceutical article that includes a container and a dilute aqueous PVP-I formulation contained in the container, wherein the container is made of polyethylene terephthalate (PET) or polypropylene (PP). The pharmaceutical article provides the aqueous PVP-I formulation with surprisingly enhanced stability over PVP-I-formulations in other pharmaceutical package forms, without the need of a stabilizing agent in the PVP-I formulations.

Abstract: The present invention provides pharmaceutical compositions comprising an antiseptic and a steroid, useful for treating a clinical symptom in a patient's airway (e.g., nose, lung, and sinus), wherein a gel containing the antiseptic is formed in situ upon instillation of the compositions onto a body cavity of a subject, as well as methods for using the same.

Abstract: The present invention provides novel slow-releasing ophthalmic compositions containing Povidone Iodine (PVP-I) and uses thereof in the treatment of acute infections of at least one eye tissue from bacterial, mycobacterial, viral, fungal, or amoebic causes and for preventing such infections in appropriate clinical settings. Each of the ophthalmic compositions contains povidone iodine, osmotic pressure regulator, suspending agent and EDTA-Na, wherein povidone iodine exists as microsphere particles formed by PVP-I and sodium alginate.